Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety and Efficacy of Percutaneous Radiofrequency Ablation (RFA) in Patients with Metastatic Gastrointestinal Stromal Tumor (GIST) with Oligoclonal Evolution of Lesions Refractory to Imatinib Mesylate (Gleevec)

Safety and Efficacy of Percutaneous Radiofrequency Ablation (RFA) in Patients with Metastatic Gastrointestinal Stromal Tumor (GIST) with Oligoclonal Evolution of Lesions Refractory to Imatinib Mesylate (Gleevec). RSNA. 2004; (RSNA):438.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.